BAY 2433334, Placebo for test product BAY 2433334 clinical trials

(20604 OCEANIC STROKE) A multicenter, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA

This study is looking for a new medicine called asundexian to help prevent strokes in people who have recently had a stroke or a mini-stroke. It compares this new medicine with a dummy pill to see if it works better and is safe.